Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Aberrant Intra- and Internetwork Functional Connectivity in Depressed Parkinson's Disease.

Wei L, Hu X, Zhu Y, Yuan Y, Liu W, Chen H.

Sci Rep. 2017 May 31;7(1):2568. doi: 10.1038/s41598-017-02127-y.

2.

Associated degeneration of ventral tegmental area dopaminergic neurons in the rat nigrostriatal lactacystin model of parkinsonism and their neuroprotection by valproate.

Harrison IF, Anis HK, Dexter DT.

Neurosci Lett. 2016 Feb 12;614:16-23. doi: 10.1016/j.neulet.2015.12.052. Epub 2015 Dec 29.

3.

Regulation of dopamine system responsivity and its adaptive and pathological response to stress.

Belujon P, Grace AA.

Proc Biol Sci. 2015 Apr 22;282(1805). pii: 20142516. doi: 10.1098/rspb.2014.2516. Review.

4.

The dopamine antagonist cis-flupenthixol blocks the expression of the conditioned positive but not the negative effects of cocaine in rats.

Wenzel JM, Su ZI, Shelton K, Dominguez HM, von Furstenberg VA, Ettenberg A.

Pharmacol Biochem Behav. 2013 Dec;114-115:90-6. doi: 10.1016/j.pbb.2013.08.014. Epub 2013 Sep 5.

5.

Hedonic and behavioral deficits associated with apathy in Parkinson's disease: potential treatment implications.

Jordan LL, Zahodne LB, Okun MS, Bowers D.

Mov Disord. 2013 Aug;28(9):1301-4. doi: 10.1002/mds.25496. Epub 2013 May 27.

6.

Mood and motor trajectories in Parkinson's disease: multivariate latent growth curve modeling.

Zahodne LB, Marsiske M, Okun MS, Rodriguez RL, Malaty I, Bowers D.

Neuropsychology. 2012 Jan;26(1):71-80. doi: 10.1037/a0025119. Epub 2011 Dec 5.

7.

Reward processing after catecholamine depletion in unmedicated, remitted subjects with major depressive disorder.

Hasler G, Luckenbaugh DA, Snow J, Meyers N, Waldeck T, Geraci M, Roiser J, Knutson B, Charney DS, Drevets WC.

Biol Psychiatry. 2009 Aug 1;66(3):201-5. doi: 10.1016/j.biopsych.2009.02.029. Epub 2009 Apr 25.

8.

Taste responses in patients with Parkinson's disease.

Sienkiewicz-Jarosz H, Scinska A, Kuran W, Ryglewicz D, Rogowski A, Wrobel E, Korkosz A, Kukwa A, Kostowski W, Bienkowski P.

J Neurol Neurosurg Psychiatry. 2005 Jan;76(1):40-6.

9.

Apathy in Parkinson's disease.

Pluck GC, Brown RG.

J Neurol Neurosurg Psychiatry. 2002 Dec;73(6):636-42.

10.

Curative effects of the atypical antidepressant mianserin in the chronic mild stress-induced anhedonia model of depression.

Moreau JL, Bourson A, Jenck F, Martin JR, Mortas P.

J Psychiatry Neurosci. 1994 Jan;19(1):51-6.

11.

Mood changes associated with "end-of-dose deterioration" in Parkinson's disease: a controlled study.

Cantello R, Gilli M, Riccio A, Bergamasco B.

J Neurol Neurosurg Psychiatry. 1986 Oct;49(10):1182-90.

12.

Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: possible role of the "hedonic" dopamine synapse.

Cantello R, Aguggia M, Gilli M, Delsedime M, Chiardò Cutin I, Riccio A, Mutani R.

J Neurol Neurosurg Psychiatry. 1989 Jun;52(6):724-31.

13.

Effects of B-HT 920 on nigrostriatal and mesolimbic dopamine systems in normosensitive and supersensitive rats.

Clarke PB, Wyder KJ, Jakubovic A, Fibiger HC.

Br J Pharmacol. 1990 Mar;99(3):509-15.

Supplemental Content

Support Center